Melanoma-specific cytotoxicity induced by a tyrosinase promoter-enhancer/herpes simplex virus thymidine kinase adenovirus

Cancer Gene Therapy

Volumn 5, Issue 5, 1998, Pages 281-291

  Siders, William M ^a   Halloran, Patrick J ^a   Fenton, Robert G ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

Herpes simplex virus thymidine kinase; Melanoma; Suicide gene; Tissue specific promoter

Indexed keywords

GANCICLOVIR; MONOPHENOL MONOOXYGENASE; THYMIDINE KINASE;

ADENOVIRUS; ANIMAL; ARTICLE; CARCINOGEN TESTING; CELL CULTURE; CELL CYCLE; CELL CYCLE S PHASE; CELL DEATH; DRUG EFFECT; ENHANCER REGION; ENZYMOLOGY; EXPERIMENTAL NEOPLASM; GENE THERAPY; GENE VECTOR; GENETICS; HERPES SIMPLEX VIRUS; HUMAN; MELANOMA; METABOLISM; METHODOLOGY; MOUSE; NUDE MOUSE; PATHOLOGY; PROMOTER REGION;

ADENOVIRIDAE; ANIMALS; CARCINOGENICITY TESTS; CELL CYCLE; CELL DEATH; ENHANCER ELEMENTS (GENETICS); GANCICLOVIR; GENE THERAPY; GENETIC VECTORS; HUMANS; MELANOMA; MICE; MICE, NUDE; MONOPHENOL MONOOXYGENASE; NEOPLASMS, EXPERIMENTAL; PROMOTER REGIONS (GENETICS); S PHASE; SIMPLEXVIRUS; THYMIDINE KINASE; TUMOR CELLS, CULTURED;

EID: 0032150507     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Chen L, Chen D, Manome Y, et al. Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses containing the DF3/MUC1 promoter. J Clin Invest. 1995;96:2775-2782.
2. Toloza EM, Hunt K, Swisher S, et al. In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector. Cancer Gene Ther. 1996;3:11-17.
3. Yang Y, Nunes FA, Berencsi K, et al. Cellular immunity to viral antigens limits El-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA. 1994;91:4407-4411.
4. + CTLs in vivo. J Immunol. 1995;155:2564-2570.
5. Siders WM, Halloran PJ, Fenton RG. Transcriptional targeting of recombinant adenoviruses to human and murine melanoma cells. Cancer Res. 1996:5638-5646.
6. Hart IR. Tissue-specific promoters in targeting systemically delivered gene therapy. Semin Oncol. 1996;23:154-158.
7. Furth PA, Hennighausen L, Baker C, et al. The variability in activity of the universally expressed human cytomegalovirus immediate early gene 1 enhancer/promoter in transgenic mice. Nucleic Acids Res. 1991;19:6205-6208.
8. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 1986;46: 5276-5281.
9. Moolten FL, Wells JM. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst. 1990;82:297-300.
10. Culver KW, Ram Z, Wallbridge S, et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science. 1992;256:1550-1552.
11. St. Clair MH, Lambe, CU, Furman PA. Inhibition by ganciclovir of cell growth and DNA synthesis of cells biochemically transformed with herpesvirus genetic information. Antimicrob Agents Chemother. 1987;31:844-849.
12. Reid R, Mar E-C, Huang E-S, et al. Insertion and extension of acyclic, dideoxy, and ara nucleotides by herpesviridae, human α, and human β polymerases: a unique inhibition mechanism for 9-(1,3-dihydroxy-2-propoxymethyl)guanine triphosphate. J Biol Chem. 1988;263:3898-3904.
13. Paulovich AG, Toczyski DP, Hartwell LH. When check-points fail. Cell. 1997;88:315-321.
14. Samejima Y, Meruelo D. "Bystander killing" induces apoptosis and is inhibited by forskolin. Gene Ther. 1995;2: 50-58.
15. Hamel W, Magnelli L, Chiarugi VP, et al. Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells. Cancer Res. 1996;56:2697-2702.
16. Freeman SM, Abboud CN, Whartenby KA, et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 1993;53: 5274-5283.
17. Bi WL, Parysek LM, Warnick R, et al. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSVtk retroviral gene therapy. Hum Gene Ther. 1993;4:725-731.
18. Fick J, Barker FGN, Dazin P, et al. The extent of heterocellular communication mediated by gap junctions is predictive of bystander tumor cytotoxicity in vitro. Proc Natl Acad Sci USA. 1995;92:11071-11075.
19. Mesnil M, Piccoli C, Tiraby G, et al. Bystander killing of cancer cells by herpes virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci USA. 1996;93: 1831-1835.
20. Dilber MS, Abedi MR, Christensson B, et al. Gap junctions promote the bystander effect of herpes virus thymidine kinase in vivo. Cancer Res. 1997;57:1523-1528.
21. Hitt M, Bett AJ, Addison CL, et al. In: Kenneth E, Adolph W, eds. Methods in Molecular Genetics. Orlando, FLorida: Academic; 1995:13-30.
22. Hemesath TJ, Steingrimsson E, McGill G, et al. Microphthalmia, a critical factor in melanocyte development, defines a discrete transcription factor family. Genes Dev. 1994;8:2770-2780.
23. Tachibana M, Perez-Jurado LA, Nakayama A, et al. Cloning of MITF, the human homolog of the mouse microphthalmia gene and assignment to chromosome 3p14.1-p12.3. Hum Mol Genet. 1994;3:553-557.
24. Bentley NJ, Eisen T, Goding CR. Melanocyte-specific expression of the human tyrosinase promoter: activation by the microphthalmia gene product and role of the initiator. Mol Cell Biol. 1994;14:7996-8006.
25. Ganss R, Montoliu L, Monaghan AP, et al. A cell-specific enhancer far upstream of the mouse tyrosinase gene confers high level and copy number-related expression in transgenic mice. EMBO J. 1994;13:3083-3093.
26. Yasumoto K-I, Yokoyami K, Shibata K, et al. Microphthalmia-associated transcription factor as a regulator for melanocyte-specific transcription of the human tyrosinase gene. Mol Cell Biol. 1994;14:8058-8070.
27. Hughes BW, Wells AH, Bebok Z, et al. Bystander killing of melanoma cells using the human tyrosinase promoter to express the Escherichia coli purine nucleoside phosphorylase gene. Cancer Res. 1995;55:3339-3345.
28. Barba D, Hardin J, Sadelain M, et al. Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci USA. 1994;91:4348-4352.
29. Ramesh R, Marrogi AJ, Munshi A, et al. In vivo analysis of the "bystander effect": a cytokine cascade. Exp Hematol. 1996;24:829-838.
30. Vile RG, Nelson JA, Castleden S, et al. Systemic gene therapy of murine melanoma using tissue-specific expression of the HSVtk gene involves an immune component. Cancer Res. 1994 54:6228-6234.
31. Yamamoto S, Suzuki S, Hoshino A, et al. Herpes simplex virus thymidine kinase/ganciclovir-mediated killing of tumor cells induces tumor-specific cytotoxic T cells in mice. Cancer Gene Ther. 1997;4:91-96.
32. Consalvo M, Mullen CA, Modesti A, et al. 5-fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory. J Immunol. 1995;154:5302-5312.
33. Golembek PT, Hamzeh FM, Jaffee EM, et al. Herpes simplex-1 virus thymidine kinase gene is unable to completely eliminate live, nonimmunogenic tumor cell vaccines. J Immunother. 1992;12:224-230.
34. Mullen CA, Petropoulos D, Lowe RM. Treatment of microscopic pulmonary metastases with recombinant autologous tumor vaccine expressing interleukin 6 and Escherichia coli cytosine deaminase suicide genes. Cancer Res. 1996;56:1361-1366.
35. Bramson JL, Hitt M, Addison CL, et al. Direct injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Hum Gene Ther. 1996;7:1995-2002.
36. O'Malley BW, Cope KA, Chen S-H, et al. Combination gene therapy for oral cancer in a murine model. Cancer Res. 1996;56:1737-1741.
37. Takana T, Kanai F, Okabe S, et al. Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing human gastric carcinoma cells in vitro. Cancer Res. 1996;65:1341-1345.
38. Kanai F, Lan K-H, Shiratori Y, et al. In vivo gene therapy for α-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene. Cancer Res. 1997;57:461-465.
39. Kaneko S, Hallenbeck P, Kotani T, et al. Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Res. 1995;55:5283-5287.
40. Hallahan DE, Mauceri HJ, Seung LP, et al. Spatial and temporal control of gene therapy using ionizing radiation. Nat Med. 1995;1:786-791.
41. Fujiwara T, Grimm EA, Mukhopadhyay T, et al. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res. 1994;54:2287-2291.
42. Clayman GL, El-Naggar AK, Roth JA, et al. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res. 1995;55:1-6.
43. Eastham JA, Hall SJ, Sehgal I, et al. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res. 1995;55:5151-5155.
44. Yang Z-Y, Perkins ND, Ohno T, et al. The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo. Nat Med. 1995;1:1052-1056.
45. Xu H-J, Zhou Y, Seigne J, et al. Enhanced tumor suppressor gene therapy via replication-deficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein. Cancer Res. 1996;56:2245-2249.
46. Zhang Y, Yu D, Xia W, et al. HER-2/neu-targeting cancer therapy via adenovirus-mediated E1A delivery in an animal model. Oncogens. 1995;10:1947-1954.
47. Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 1996;274:373-376.